AnaptysBio, Inc.

AnaptysBio announced its intention to separate into two independent publicly traded companies by year-end 2026, aiming to unlock shareholder value by creating distinct business models. The 'Royalty Management Co' will manage significant royalty streams, primarily from GSK's Jemperli, which is projected to achieve over $2.7 billion in peak sales and could generate up to $390 million annually for Anaptys after the Sagard paydown, anticipated by mid-2027. Concurrently, the 'Biopharma Co' will focus on advancing its pipeline of immune cell modulating antibodies, including rosnilimab (with positive Phase IIb data in RA and upcoming UC results), ANB033, and ANB101, launching with at least two years of operational funding. This strategic move addresses the current undervaluation of the combined entity and provides flexibility for rosnilimab's future development and capitalization.

Analysis

AnaptysBio has announced a strategic corporate separation, intended to be completed by year-end 2026, to bifurcate its high-value royalty assets from its clinical-stage biopharma operations. The core rationale is to unlock value, as management asserts the company's current valuation does not reflect the worth of its royalty stream alone, a conviction supported by a recent repurchase of 10% of outstanding shares. The newly formed "Royalty Management Co" will be a pure-play entity holding the rights to GSK's blockbuster drug, Jemperli. Jemperli's sales are on a steep growth trajectory, reaching $262 million in Q2 2025, and GSK projects peak sales exceeding $2.7 billion, which could translate to $390 million in annual royalties for Anaptys. These cash flows are expected to materialize for the new entity following the paydown of a $600 million obligation to Sagard, projected to complete between mid-2027 and Q2 2028. Concurrently, the "Biopharma Co" will advance the existing pipeline, including the lead asset rosnilimab, which has upcoming Phase II data in ulcerative colitis. This entity will be launched with a capital runway of at least two years. A key variable in the separation is the strategic path for rosnilimab; management noted that a potential partnership or financing decision for this asset could influence the final economic allocation between the two new companies, introducing an element of structural uncertainty.

Key Decisions for Investors

• Investors should evaluate AnaptysBio as a sum-of-the-parts story, as the announced separation is explicitly designed to crystallize the distinct values of the Jemperli royalty stream and the clinical-stage pipeline.
• The upcoming Phase II data for rosnilimab in ulcerative colitis, expected in November or December, is a critical near-term catalyst that will significantly impact the valuation of the future 'Biopharma Co' and influence strategic decisions.
• Monitor GSK's quarterly sales of Jemperli to track the velocity of the Sagard obligation paydown, as this directly determines the timeline for when the 'Royalty Management Co' will begin generating direct cash flow for its shareholders, estimated to commence between mid-2027 and Q2 2028.
• Consider the structural ambiguity regarding rosnilimab, as management has indicated its strategic path could alter the economic split between the two new entities, representing a key variable to watch before the separation is finalized in 2026.